Introduction
It has been previously demonstrated (Geliert et al, 1977; Campbell, 1980) that neonatal adminis¬ tration of oestradiol benzoate results in impaired uterine growth responses to exogenous oestradiol in the prepubertal rat. This reduction in uterine responsivity is the result of a decrease in available cytoplasmic oestrogen binding sites in the uterus with a concomitant decrease in the nuclear reten¬ tion of the receptor-oestrogen complex by uterine nuclei (Geliert et al, 1977; Campbell, 1980) . Additionally, neonatal exposure to oestradiol benzoate impairs the capacity of the uterus to metabolize glucose under oestrogen stimulation (Campbell, 1980) . The latter effect augments the severity of disturbance of uterine function by neonatal oestrogenization in contrast to that produced by neonatal androgenization.
The purpose of the experiments reported herein was therefore to determine whether the antioes¬ trogens CI-628 and nafoxidine would allay the effects of neonatal oestrogenization by oestradiol benzoate or whether their agonist properties would prevail over their antagonistic action.
Materials and Methods
Preparation of animals and materials. Rats of the Sprague-Dawley strain (SAF/SDD) were obtained from Southern Animal Farms (Prattville, AL) and maintained in a controlled environment in the UAH animal facility with a lighting schedule of 13 h light: 11 h dark (lights on 07:00 h). Commercially pelleted food (Purina) and water were provided ad libitum.
Young were designated 1 day old on the morning of discovery, and litters were culled to a maximum of 8 females with only one treatment group housed with a given mother. All experiments used animals from a minimum of two different litters. Neonates were injected subcutaneously (s.c.) with peanut oil vehicle (0-1 ml), 50 µg CI-628 (a-{4-pyrrolidinoethoxy}-phenyl-4-methoxy-a-nitrostilbene) or 50 µg nafoxidine (l-2-{p-(3,4-dihydro-6-methoxy-2-phenyl-l-naphthy) (Korenman, 1968 (Anderson et al, 1973) . The uteri were stripped of adhering connective tissue and placed into 25 ml Erlenmeyer flasks containing 2 ml Eagles medium (Difco; Detroit, MI) and 10~6 M-[U-14C]glucose (0-5 µ total activity). The flasks were aerated with 95% 02-5% C02 and sealed with rubber serum stoppers contain¬ ing filter paper wicks soaked with 0-25 ml methyl benzonium hydroxide to trap evolved 14C02. The flasks were incubated 1 h at 37°C after which I -5 ml 5 N-H2S04 was injected through the serum stoppers to halt the reaction and promote the release of carbon dioxide from the incubation medium. After an additional 2 h incubation at 37°C, the 14C02 which had been absorbed onto the filter paper wick was determined by placing the wick into 10 ml Aquasol-2 and counting the radioactivity.
Determination of actomyosin. Ovariectomized adult rats were injected s.c. for 6 consecutive days with 5 µg oestradiol-17ß/100g body weight. Uteri were obtained 24 h after the last injection and kept frozen at -20°C until the actomyosin content could be analysed. The extraction and estimation of actomyosin was carried out according to the procedure described by Needham & Williams (1963) . To quantitate actomyosin content, 2 or 3 uteri from the same treatment group were placed into an ice-cold solution containing three times the uterine volume of 0-5M-KC1 buffered with 0-04m-K2HPO4 (pH71) and 1/50 of the volume of 01 m-ATP adjusted to pH 7-4 with Trizma base. The uteri were homogenized using a Polytron homogenizer and the homogenate was centrifuged at 1000 g for 10 min at 4°C. The supernatant was decanted and reserved for later actomyosin esti¬ mation. The pellet was resuspended at two times the uterine volume with the buffered KC1 solution and then centrifuged again for 10 min. The two supernatant pools were combined and stored overnight at 4°C to permit ATP degradation.
Viscosity Figure 2 indicates that oestrogen stimulation of glucose oxidation in the prepubertal rat uterus was significantly reduced from control levels (P < 0025) in animals which had been treated neo¬ natally with oestradiol benzoate or nafoxidine alone or with oestradiol benzoate in combination with either of the antioestrogens. The mean value for each of these treatments did not differ from the average of the unstimulated control group which was injected with saline instead of oestradiol 3 h before assay. The metabolic response to oestradiol in the treatment groups resembled that observed in rats which had been neonatally ovariectomized. Thus, only neonatal treatment with CI-628 alone did not produce an adverse effect on this uterine response.
An experiment to determine the extent to which the antioestrogens CI-628 or nafoxidine deplete specific cytoplasmic oestrogen binding site availability 24 h after neonatal injection was also con¬ ducted (Table 1) . Nafoxidine given as a single 50 pg injection 24 h before assay for cytoplasmic oestrogen binding by the charcoal-dextran procedure reduced the measured estimation of control uterine cytosolic receptor by 81-5%. The same dose of CI-628 produced a 72-8% depletion of cytoplasmic oestrogen binding, sites in the uterus.
The ovarian weights of prepubertal rats treated neonatally with steroid hormone ester and/or antioestrogen are given in Table 2 . A significant reduction (P < 005) in ovarian weights was evi¬ dent for all treatment groups when compared to the peanut oil vehicle-injected controls. This reduction in prepubertal ovarian weight in treatment groups is largely coincident with reduced oestrogen binding sites in the uterus and the impairment of oestrogen-stimulated glucose metab¬ olism. However, only the relationship between the relative magnitude of ovarian weight reduction as a consequence of the different neonatal treatments and the degree to which uterine glucose metabolism is compromised exhibits a significant correlation coefficient (P < 0-05). The effect of neonatal treatment with oestradiol benzoate alone or 24 h after prior treatment with nafoxidine or CI-628 upon oestrogenic induction of uterine actomyosin in adulthood is pre¬ sented in Table 3 . Uteri from animals treated neonatally with oestradiol benzoate exhibited a significant reduction (P < 005) from control actomyosin production. In rats in which both antioestrogens had been administered 24 h before neonatal oestradiol benzoate injection, inter¬ mediate organ concentrations of actomyosin were evident after oestrogen treatment in adulthood. However, when uterine actomyosin content was expressed on the basis of total uterine protein, the relative actomyosin content in animals treated neonatally with antioestrogen plus oestradiol benzoate is similar to that seen in control animals. tlnjections given 24 h apart. **P < 0005 (Dunnett's test) compared with control. The ovarian weight reduction observed in the prepubertal rat treated neonatally with steroid ester or antioestrogen probably represents feedback suppression of gonadotrophin secretion due to the introduction of exogenous agonist (Clark et al, 1973; Geliert et al, 1977; Campbell, 1980 (Campbell, 1980; Campbell & Modlin, 1987 (Clark & Gorski, 1970 (Geliert et al, 1971; Clark & McCormack, 1977; Chamness et al, 1979; McCormack & Clark, 1979; Clark et al, 1982; Dohler et al, 1986) .
Neonatal treatment with nafoxidine or CI-628 before neonatal injection of oestradiol benzoate 24 h later, however, did prevent the oestradiol-induced reduction of oestrogen-stimulated produc¬ tion of actomyosin in adult rat uteri. The hyperoestrogenization of the uterus due to antioestrogen exposure occurs principally in the endometrium: the antioestrogens do not affect the myometrium acutely or developmentally on histological or biochemical bases while oestradiol affects luminal epithelium, stroma and myometrium (Markaverich et al, 1981; Clark et al., 1982) . Therefore, in tissue in which both antioestrogens lack agonist properties, their antagonist actions appear to prevail.
Although we observed some apparent cytoplasmic oestrogen binding sites remaining after neonatal antioestrogen injection, these residual binding sites may not be available for subsequent nuclear translocation (Williams & Gorski, 1974) . Moreover, depletion of all cytoplasmic receptors does not appear to be a prerequisite for the antagonistic action of the antioestrogens (Hayes et al, 1981) . However, the mechanism of action of the antioestrogens upon reproductive tract develop¬ ment is complicated by the presence of specific antioestrogen binding sites distinct from oestrogen receptors in a number of tissues in the rat, including the uterus and ovary (Sutherland et al, 1980; Winneker & Clark, 1983; Sudo et al, 1983) . Indeed, it has been proposed that antioestrogen inter¬ action with such binding sites may alter biological potencies and pharmacokinetics to produce differential effects (Sudo et al, 1983) . Clearly, the possibility that antioestrogen binding sites may mediate some of the effects of the antioestrogens needs to be examined.
Furthermore, previous reports have indicated that antioestrogens are uterotrophic in the neonatal rat (Clark et al, 1982; Clark & Guthrie, 1983) . The results described herein also con¬ firm the prominent agonist properties of the antioestrogens CI-628 and nafoxidine on neonatal reproductive tract tissues. Each antioestrogen produces prepubertal reproductive deficits that differentially mimic those produced by oestradiol benzoate, while neither antioestrogen blocks the oestradiol-induced impairment which is not produced when the antioestrogen is administered alone to the neonatal rat.
Since some antioestrogens are being used clinically to induce ovulation in anovulatory women and to inhibit breast cancer, the dual potential of these compounds needs to be recognized to avoid unexpected and perhaps undesirable side effects. The results reported in this work therefore reaffirm and extend the caution raised previously in using these drugs during pregnancy and/or the perinatal period (Clark & McCormack, 1977; McCormack & Clark, 1979; Chamness et al, 1979) . In addition to the structural and functional reproductive anomalies previously observed in adulthood, it is evident from this study that early, prepubertal alterations at the molecular level also occur as a consequence of exposure to antioestrogens early in life.
